Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
Read Now: TheBodyPRO.com Covers AIDS 2014
  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

U.S. News

Strides Arcolab Receives Tentative FDA Approval For Efavirenz Under PEPFAR Review Process

March 30, 2007

Indian pharmaceutical company Strides Arcolab on Wednesday announced that it has received tentative FDA approval for the tablet form of its generic antiretroviral drug Efavirenz under the expedited review guidelines of the President's Emergency Plan for AIDS Relief, PTI/The Hindu reports (PTI/The Hindu, 3/28). The tentative approval designation means the generic drug meets FDA safety and efficacy standards but cannot be sold in the U.S. because of existing patents or exclusivity agreements, although it can be used by organizations outside the U.S. under PEPFAR (Kaiser Daily HIV/AIDS Report, 8/2/06). Efavirenz is the generic version of Bristol-Myers Squibb's Sustiva (PTI/The Hindu, 3/28). The drug is used in combination therapies, as well as in drug regiments for people on concurrent treatment for tuberculosis. Arun Kumar, Strides Arcolab's vice chair and managing director, said that the tentative FDA approval "will give [a] major boost to our AIDS, TB and malaria initiative, particularly in Africa and South Asian countries" (Strides Arcolab release, 3/28).

Back to other news for March 30, 2007


Reprinted with permission from kaisernetwork.org. You can view the entire Kaiser Daily HIV/AIDS Report, search the archives, or sign up for email delivery at www.kaisernetwork.org/dailyreports/hiv. The Kaiser Daily HIV/AIDS Report is published for kaisernetwork.org, a free service of the Kaiser Family Foundation, by The Advisory Board Company. © 2007 by The Advisory Board Company and Kaiser Family Foundation. All rights reserved.



  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily HIV/AIDS Report. Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.
 
See Also
More HIV News

Tools
 

Advertisement